Pnu 74654

Manufactured by Santa Cruz Biotechnology

Sourced in Canada, United States

PNU-74654 is a laboratory product manufactured by Santa Cruz Biotechnology. It is a chemical compound used for research purposes. The core function of PNU-74654 is to serve as a research tool, but no further details on its intended use can be provided in an unbiased and factual manner.

Automatically generated - may contain errors

Lab products found in correlation

Ascorbic acid, by Merck Group (1 mentions) Phospho gsk3β, by Cell Signaling Technology (1 mentions) Eif4e, by Cell Signaling Technology (1 mentions) Phospho cyclin d1, by Cell Signaling Technology (1 mentions) Alexa conjugated secondary antibody, by Cell Signaling Technology (1 mentions) Phospho gsk3α, by Cell Signaling Technology (1 mentions) Mg132, by Merck Group (1 mentions) Vectashield mounting medium, by Vector Laboratories (1 mentions) 3 4 5 dimethylthiazol 2 yl 2 5 diphenyl tetrazolium bromide mtt, by Roche (1 mentions) 5 bromo 4 chloro 3 indolyl β d galactopyranoside x gal, by Roche (1 mentions)

4 protocols using pnu 74654

Photodynamic Activation of Hair Follicles

Check if the same lab product or an alternative is used in the 5 most similar protocols

A modified (patented for all commercial purposes) PpIX-dependent photodynamic treatment was used to activate a transient production of non-lethal endogenous ROS levels in human hair follicles in vivo. To this end, FUs were incubated for 4 hours with 0,1–1 mM of MAL (Sigma) in complete Williams E medium, and then irradiated 10 min with a red light emitting diode source with an emission peak at 634 nm bandwidth, with a total light dose of 3.72 J/cm². Light controls with no MAL were included in all experimental designs. PT + inh condition was carried out adding the ROS scavengers N-acetil-L-Cysteine and Ascorbic Acid (NAC and AA, both from Sigma-Aldrich) at a final concentration of 3 mM and 100 µM, respectively, 30 min before red light exposure, to impair the effects associated to ROS. After treatments, fresh medium was added. In order to inhibit WNT signaling activity, the specific inhibitor PNU-74654 (Santa Cruz Biotech) was used at a final concentration of 40 µM, diluted in complete Williams medium E. PNU-74654 was initially added to the medium at the same that MAL and was maintained until the end of experiments, replacing every day with fresh medium containing the inhibitor.

Calvo-Sánchez M.I., Fernández-Martos S., Montoya J.J, & Espada J. (2019). Intrinsic activation of cell growth and differentiation in ex vivo cultured human hair follicles by a transient endogenous production of ROS. Scientific Reports, 9, 4509.

+ Open protocol

+ Expand

Wnt/β-catenin Inhibitors and Their Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols

Wnt/β-catenin inhibitors, iCRT3 and PNU-74654, were from Santa Cruz Biotechnology (Santa Cruz, CA). MG-132, was obtained from Sigma-Aldrich Chemical Co., Inc. (St. Louis, MO). Vectashield mounting medium was from Vector Laboratories Inc. (Burlingame, CA). siRNA for β-catenin was from Dharmacon (Lafayette, CO). Rabbit antibodies to cyclin D1, GSK3α, GSK3β, phospho GSK3α, phospho GSK3β, phospho cyclin D1, eukaryotic initiation factor 4E (eIF4E) and Alexa-conjugated secondary antibodies were from Cell Signaling Technology Inc. (Beverly, MA). Anti-eIF4E (phospho S209) antibody was from Abcam Inc. (Cambridge, MA). Extracellular domain of receptor for advanced glycation end products (sRAGE) was prepared as described (11 (link)). All other reagents were provided as described (11 (link),12 ). Scrambled siRNA was used as negative control for all siRNA experiments as described (11 (link),12 ). PolyP-70 was a generous gift from Dr. James Morrissey (University of Illinois, Urbana). Platelets releasates were prepared by activation of human platelets with TRAP as described (21 (link)).

Hassanian S.M., Ardeshirylajimi A., Dinarvand P, & Rezaie A.R. (2016). Inorganic polyphosphate promotes cyclin D1 synthesis through activation of mTOR/Wnt/β-catenin signaling in endothelial cells. Journal of thrombosis and haemostasis : JTH, 14(11), 2261-2273.

+ Open protocol

+ Expand

Wnt/beta-catenin Pathway Inhibitor Efficacy

Check if the same lab product or an alternative is used in the 5 most similar protocols

Glucose was purchased from Merck (CAS 77938-63-7; Darmstadt, Germany). The inhibitor of Wnt/beta-catenin pathway PNU-74654 (CAS 113906-27-7) was from Santa Cruz Biotechnology (Santa Cruz, USA), and both 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 5-bromo-4-chloro-3-indolyl-β-Dgalactopyranoside (X-Gal) were from Roche Diagnostics (Mannheim, Germany

Asghari M., Nasoohi N, & Hodjat M. (2021). High glucose promotes the aging of human dental pulp cells through Wnt/beta-catenin signaling. Dental and medical problems, 58(1).

+ Open protocol

+ Expand

Intrathecal Wnt Inhibitors in Diabetic Rats

Check if the same lab product or an alternative is used in the 5 most similar protocols

LGK974, NSC668036, and PNU74654 (Wnt signaling inhibitors) were purchased from Santa Cruz Biotechnology (Santa Crus, California) and the doses (10 and 30 µmol/L) were selected based on previous literature. 25, 36, 57 Wnt signaling inhibitors were dissolved in DMSO (10% v/v) and injected intrathecally (using Hamilton syringe with a 30G needle) to anesthetized animals (anesthesia used was halothane) between L5 and L6 lumbar vertebrae in a volume of 20 μL/rat on 3 consecutive days to 6-week diabetic rats (Fig 1). No adverse events were reported with the treatment of inhibitors in diabetic and control group animals injected with the inhibitors.

Resham K, & Sharma S.S. (2019). Pharmacologic Inhibition of Porcupine, Disheveled, and β-Catenin in Wnt Signaling Pathway Ameliorates Diabetic Peripheral Neuropathy in Rats. The journal of pain, 20(11).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!